Actively Recruiting

Phase 1
Phase 2
Age: 6Years +
All Genders
NCT06834035

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

Led by M. Peter Marinkovich · Updated on 2026-05-05

8

Participants Needed

1

Research Sites

82 weeks

Total Duration

On this page

Sponsors

M

M. Peter Marinkovich

Lead Sponsor

E

Epidermolysis Bullosa Research Partnership

Collaborating Sponsor

AI-Summary

What this Trial Is About

The study objective is to see if IV IgG treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin in conjunction with VYJUVEK treatment improves wound healing and affects the levels of C7 and HSV-1 antibody levels in serum. Fewer wounds, more rapidly healing wounds, and decreased C7 and HSV-1 antibodies could improve quality of life.

CONDITIONS

Official Title

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

Who Can Participate

Age: 6Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of generalized Recessive dystrophic epidermolysis bullosa (RDEB) confirmed by COL7A1 mutations
  • Diagnosis of Epidermolysis Bullosa Acquisita (EBA) with serum C7 antibody levels above normal range
  • Baseline skin blistering greater than 5% of total body surface area
  • At least one wound 20 cm² or larger that can be treated entirely with VYJUVEK weekly
  • At least one wound 20 cm² or larger that has never been treated with VYJUVEK
  • Ongoing VYJUVEK treatment
Not Eligible

You will not qualify if you...

  • History of blood clotting events (thrombotic events)
  • History of heart failure
  • History of kidney failure
  • IgA deficiency

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Stanford University

Redwood City, California, United States, 94163

Actively Recruiting

Loading map...

Research Team

K

Kunju Clinical Research Coordinator, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa | DecenTrialz